Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review
CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143 (Source: Current Drug Delivery)
Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research
Recent trends in nanoparticulate delivery system for amygdalin as potential therapeutic herbal bioactive agent for cancer treatment
Curr Drug Deliv. 2023 Nov 27. doi: 10.2174/0115672018280381231119150732. Online ahead of print.ABSTRACTCancer is the deadliest and most serious health problem. The mortality rate of cancer patients has increased significantly worldwide in recent years. There are several treatments available, but these treatments have many limitations, such as non-specific targeting, toxicity, bioavailability, solubility and permeability problems, serious side effects, and a higher dose. Many people prefer phytomedicine because it has fewer side effects. However, amygdalin is a naturally occurring phytoconstituent. It has many harmful effec...
Source: Current Drug Delivery - December 1, 2023 Category: Drugs & Pharmacology Authors: Mahendra Prajapati Dr Rohitas Deshmukh Dr Ranjit K Harwansh Source Type: research
Recent trends in nanoparticulate delivery system for amygdalin as potential therapeutic herbal bioactive agent for cancer treatment
Curr Drug Deliv. 2023 Nov 27. doi: 10.2174/0115672018280381231119150732. Online ahead of print.ABSTRACTCancer is the deadliest and most serious health problem. The mortality rate of cancer patients has increased significantly worldwide in recent years. There are several treatments available, but these treatments have many limitations, such as non-specific targeting, toxicity, bioavailability, solubility and permeability problems, serious side effects, and a higher dose. Many people prefer phytomedicine because it has fewer side effects. However, amygdalin is a naturally occurring phytoconstituent. It has many harmful effec...
Source: Current Drug Delivery - December 1, 2023 Category: Drugs & Pharmacology Authors: Mahendra Prajapati Dr Rohitas Deshmukh Dr Ranjit K Harwansh Source Type: research
Recent trends in nanoparticulate delivery system for amygdalin as potential therapeutic herbal bioactive agent for cancer treatment
Curr Drug Deliv. 2023 Nov 27. doi: 10.2174/0115672018280381231119150732. Online ahead of print.ABSTRACTCancer is the deadliest and most serious health problem. The mortality rate of cancer patients has increased significantly worldwide in recent years. There are several treatments available, but these treatments have many limitations, such as non-specific targeting, toxicity, bioavailability, solubility and permeability problems, serious side effects, and a higher dose. Many people prefer phytomedicine because it has fewer side effects. However, amygdalin is a naturally occurring phytoconstituent. It has many harmful effec...
Source: Current Drug Delivery - December 1, 2023 Category: Drugs & Pharmacology Authors: Mahendra Prajapati Dr Rohitas Deshmukh Dr Ranjit K Harwansh Source Type: research
